Centrum is bullish on Marksans Pharma has recommended buy rating on the stock with a target price of Rs 55 in its research report dated February 20, 2018.
Centrum's research report on Marksans Pharma
We upgrade Marksans Pharma (MPL) to Buy from Hold rating with a TP of Rs55 (earlier Rs45) based on 18x March’20E EPS of Rs3.0. MPL’s Q3FY18 revenues and EBIDTA were lower than our expectations but net profit was in-line with the expectations. The drug maker’s Q3FY18 revenue grew 2% YoY, EBIDTA margin improved 80bps to 13.3% and net profit grew 72% YoY. The Goa facility was approved by UK MHRA and TGA-Australia. We expect MPL’s performance to improve led by the recent launch of four new products in the US and expected approvals for softgel capsules from US FDA. Key positive trigger to our assumption includes stupendous growth in the US market and key negative risk includes regulatory issues for the Goa facility from US FDA.
Outlook
We have revised our FY18E and FY19E EPS downwards by 3% and 19% respectively. We upgrade MPL to Buy from Hold rating, with a TP of Rs55 based on 18x March’20E EPS of Rs3.0, and a 45.3% upside from CMP. Key positive upsides would be additional ANDA approvals from US FDA and key negative would be regulatory issue with US FDA for its Goa facility.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More
